Skip to main content

Table 3 Validation results

From: Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis

   N Urine concentration P
AAT MCD 13 / 14 193.5 (102.49 –580.0) μg/ml 0.002
FSGS 14 / 14 20.93 (10.45 –101.65) μg/ml
TF MCD 12 / 14 653.63 (241.27 –1,348.38) μg/ml 0.002
FSGS 14 / 14 129.96 (55.41 –267.10) μg/ml
HTN-3 MCD 5 / 14 0.35 (0.32 –0.48) μg/ml 0.03
FSGS 3 / 14 0.22 (0.17 –0.23) μg/ml
MRPL17 MCD 12 / 14 242.98 (174.25 –534.75) pg/ml 0.001
FSGS 14 / 14 111.86 (74.90 –154.78) pg/ml
PCNP MCD 14 / 14 441.67 (152.50 –503.10) pg/ml 0.72
FSGS 12 / 14 348.55 (216.25 –437.70) pg/ml
CALB2 MCD 14 / 14 3.52 (2.88 –4.40) pg/ml 0.002
FSGS 14 / 14 6.98 (4.29 –8.65) pg/ml
CCNY MCD 12 / 14 87.60 (83.40 –91.15) pg/ml 0.71
FSGS 12 / 14 87.70 (84.30 –102.2) pg/ml
PTAFR MCD 5 / 14 0.84 (0.46 –0.98) ng/ml 0.25
FSGS 2 / 14 0.51 (0.36 –0.66) ng/ml
  1. N represents the number of urine samples in which the proteins were detected by ELISA